The Effect of Diflunisal on Familial Transthyretin Amyloidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An ongoing trial of diflunisal has been closed for enrollment, thus, patients suitable for the study can no longer participate or receive treatment by diflunisal; and patients, who have participated in the trial can not continue their treatment. The investigators want to continue to monitor the effect of the drug on transthyretin (TTR) amyloidosis in an open label observational study.

Primary endpoint will be a composite score of the manifestations of the disease (Kumamoto scale) and secondary end points will be measurements of neurological impairment, heart involvement and nutritional status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

NCT00607581

Amyloidosis

COMPLETED PHASE2

Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation

NCT01606280

Amyloidosis

COMPLETED

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

NCT04298372

Amyloidosis Cardiac

COMPLETED PHASE3

A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

NCT05235269

Amyloidosis

COMPLETED PHASE2

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

NCT01148953

Transthyretin Mediated Amyloidosis (ATTR)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Duration of treatment in this study is dependent of the results from the ongoing IND 68092-study, which are planned to be presented 2013.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diflunisal

Film-coated tablet, 250 mg twice daily, orally for approximately 2 years

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy and genetically proven systemic transthyretin amyloidosis caused by a TTR gene mutation. The amyloid shall be proven to be of transthyretin type, and the fibril composition settled.
* Age ≥ 18 years.
* Negative pregnancy test and contraception for sexually active women of child bearing potential.

Exclusion Criteria

* Concomitant use of non-study non-steroidal anti-inflammatory drugs (NSAIDs)
* Heart failure with symptoms at daily activities (NYHA class ≥III)
* Renal insufficiency (creatinine clearance \< 30 ml calculated from the Cockcroft-Gault formula)
* Active non-haemorrhoidal bleeding within the last 18 month.
* Non-treated peptic ulcer disease.
* Anticoagulation therapy, low dose ASA permitted.
* Non-steroidal or aspirin allergy/hypersensitivity
* Thrombocytopenia (\< 100,000 platelets/mm3)
* Inability or unwillingness of subject to give written informed consent
* By the investigator regarded as unable to follow the study guidelines and scheduled controls.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No